|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
130,450,000 |
Market
Cap: |
1.43(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$4.06 - $11.48 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 825 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Cogent Biosciences is a biotechnology company focused on developing therapies for genetically defined diseases. Co.'s approach is to design therapies that treat the underlying cause of disease and improve the lives of patients. Co.'s main program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. Bezuclastinib is a highly selective KIT inhibitor with the potential to provide a new treatment option for these patient populations. In addition, Co.'s research team is developing a portfolio of targeted therapies to help patients fighting serious, genetically driven diseases.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
800,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$9,600,000 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fmr Corp |
See Remark 1 |
|
2018-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
2,318,538 |
23,240 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2018-04-03 |
4 |
B |
$12.00 |
$1,128,624 |
I/I |
94,052 |
452,115 |
0.01 |
- |
|
Fil Ltd |
See Remark 1 |
|
2018-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
1,138,274 |
1,138,274 |
|
- |
|
Ratcliffe Liam |
Director |
|
2018-04-03 |
4 |
B |
$12.00 |
$6,600,000 |
I/I |
550,000 |
897,773 |
2.1 |
- |
|
Ratcliffe Liam |
Director |
|
2018-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
1,245,545 |
622,773 |
|
- |
|
Atlas Venture Associates Ix, Llc |
10% Owner |
|
2018-04-03 |
4 |
B |
$12.00 |
$1,128,624 |
D/D |
94,052 |
3,361,535 |
2.45 |
- |
|
Atlas Venture Associates Ix, Llc |
10% Owner |
|
2018-04-03 |
4 |
A |
$0.00 |
$0 |
D/D |
3,267,483 |
3,267,483 |
|
- |
|
Booth Bruce |
Director |
|
2018-04-03 |
4 |
B |
$12.00 |
$1,128,624 |
I/I |
94,052 |
3,361,535 |
2.1 |
- |
|
Booth Bruce |
Director |
|
2018-04-03 |
4 |
A |
$0.00 |
$0 |
I/I |
3,267,483 |
3,267,483 |
|
- |
|
59 Records found
|
|
Page 3 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|